Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Capital Expenditures (2024 - 2025)

CG Oncology's Capital Expenditures history spans 2 years, with the latest figure at $7000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 96.65% year-over-year to $7000.0; the TTM value through Dec 2025 reached $134000.0, down 42.74%, while the annual FY2025 figure was $134000.0, 42.74% down from the prior year.
  • Capital Expenditures reached $7000.0 in Q4 2025 per CGON's latest filing, down from $97000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $209000.0 in Q4 2024 to a low of -$1000.0 in Q3 2024.